ADAP Crisis Task Force Announces Groundbreaking Agreement with AbbVie for Hepatitis C Treatment Viekira Pak™

The ADAP Crisis Task Force (Task Force) has reached a new pricing agreement between AbbVie and AIDS Drug Assistance Programs (ADAPs) for Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets) for the treatment of hepatitis C (HCV). AbbVie is the first company to offer a discount on the ADAP price of an HCV medication in the era of new curative HCV treatments. The agreed-upon ADAP price for Viekira Pak, negotiated between the Task Force and AbbVie, reflects voluntary discounts and rebates that are significantly lower than the wholesale acquisition cost (WAC). Read more here...http://nastad.org/docs/ACTF-Press-Release-AbbVie-January-2015.pdf

oldestnewest

    You may also like...